Intracellular targets of cyclin-dependent kinase inhibitors: Identification by affinity chromatography using immobilised inhibitors

Chemistry and Biology

Volumn 7, Issue 6, 2000, Pages 411-422

  Knockaert, M ^a   Gray, N ^b   Damiens, E ^a   Chang, Y T ^c   Grellier, P ^d   Grant, K ^e   Fergusson, D ^e   Mottram, J ^e   Soete, M ^f   Dubremetz, J F ^f   Le Roch, K ^g   Doerig, C ^g   Schultz, P G ^b   Meijer, L ^a  

^a STATION BIOLOGIQUE   (France)

^b Novartis Inst for Funct Genomics   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

^d CNRS   (France)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

^f INSTITUT PASTEUR DE LILLE   (France)

^g INSERM   (France)

Author keywords

Casein kinase 1; Cyclin dependent kinases; erk; Malaria; Purine

Indexed keywords

AFFINITY CHROMATOGRAPHY; CASEIN KINASE I; CULTURE MEDIUM; CYCLIN DEPENDENT KINASE; ENZYME INHIBITOR; LEISHMANIA MEXICANA; OLOMOUCINE; PLASMODIUM FALCIPARUM; PURINE DERIVATIVE; PURVALANOL; TOXOPLASMA GONDII; TRYPANOSOMA CRUZI;

LEISHMANIA MEXICANA; PLASMODIUM FALCIPARUM; TOXOPLASMA GONDII; TRYPANOSOMA; TRYPANOSOMA CRUZI;

EID: 0034086397     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1074-5521(00)00124-1     Document Type: Article

References (49)

1. Dunphy, W.G. (ed.) (1997). Cell cycle control. Methods Enzymol., 283, 678.
2. Morgan D. Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu. Rev. Cell Dev. Biol. 13:1997;261-291.
3. Vogt P.K., Reed S.I. Cyclin dependent kinase (CDK) inhibitors. Curr. Top. Microbiol. Immunol. 227:1998;1-169.
4. Stein G.S., Baserga R., Giordano A., Denhardt D.T. The Molecular Basis of Cell Cycle and Growth Control. 1999;Wiley-Liss Inc, New York.
5. Senderowicz A., Sausville E.A.et al. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J. Clin. Oncol. 16:1998;1-17.
6. Garrett M.D., Fattaey A. CDK inhibition and cancer therapy. Curr. Opin. Genet. Dev. 9:1999;104-111.
7. Meijer L. Chemical inhibitors of cyclin-dependent kinases. Trends Cell Biol. 6:1996;393-397.
8. Meijer L., Kim S.H. Chemical inhibitors of cyclin-dependent kinases. Methods Enzymol. 283:1997;113-128.
9. Meijer L., Leclerc S., Leost M. Properties and potential applications of chemical inhibitors of cyclin-dependent kinases. Pharmacol. Ther. 82:1999;279-284.
10. Gray N.S., Détivaud L., Doerig C., Meijer L. ATP-site directed inhibitors of cyclin-dependent kinases. Curr. Med. Chem. 6:1999;859-875.
11. suc1-coated microtitration plates. Anticancer Res. 11:1991;1581-1590.
12. Kitagawa M., Okuyama A.et al. Butyrolactone I, a selective inhibitor of cdk2 and cdc2 kinase. Oncogene. 8:1993;2425-2432.
13. Vesely J., Meijer L.et al. Inhibition of cyclin-dependent kinases by purine derivatives. Eur. J. Biochem. 224:1994;771-786.
14. Losiewiecz M.D., Carlson B.A., Kaur G., Sausville E.A., Worland P.J. Potent inhibition of cdc2 kinase activity by the flavonoid L86-8275. Biochem. Biophys. Res. Commun. 201:1994;589-595.
15. De Azevedo W.F., Leclerc S., Meijer L., Havlicek L., Strnad M., Kim S-H. Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. Eur. J. Biochem. 243:1997;518-526.
16. Meijer L., Moulinoux J.P.et al. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 & cdk5. Eur. J. Biochem. 243:1997;527-536.
17. Gray N.S., Schultz P.G.et al. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science. 281:1998;533-538.
18. Hoessel R., Meijer L.et al. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat. Cell Biol. 1:1999;60-67.
19. Schultz C., Kunick C.et al. The Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity. J. Med. Chem. 42:1999;2909-2919.
20. Zaharevitz D., Sausville E.A.et al. Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases. Cancer Res. 59:1999;2566-2569.
21. Meijer L., Pettit G.R.et al. Inhibition of cyclin-dependent kinases 1, 2 & 5, GSK-3β and casein kinase 1 by hymenialdisine, a marine sponge constituent. Chem. Biol. 7:2000;51-63.
22. Brooks E.E., Shiffman D.et al. CVT-313, a specific and potent inhibitor of CDK2 that prevents neointimal proliferation. J. Biol. Chem. 272:1997;29207-29211.
23. Suzuki J.I., Sekiguchi M.et al. Prevention of graft coronary arteriosclerosis by antisense cdk2 kinase oligonucleotide. Nature Med. 3:1997;900-903.
24. Pippin J.W., Qu Q., Meijer L., Shankland S.J. Direct in vivo inhibition of the nuclear cell cycle cascade in experimental mesangial proliferative glomerulonephritis with roscovitine, a novel CDK2 antagonist. J. Clin. Invest. 100:1997;2512-2520.
25. Shankland S.J. Cell-cycle control and renal disease. Kidney Int. 52:1997;294-308.
26. Bresnahan W.A., Boldogh I., Chi P., Thompson E.A., Albrecht T. Inhibition of cellular cdk2 activity blocks human cytomegalovirus replication. Virology. 231:1997;239-247.
27. Mancebo H.S.Y., Flores O.et al. P-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro. Genes Dev. 11:1997;2633-2644.
28. Schang L.M., Phillips J., Schaffer P.A. Requirement for cellular cyclin-dependent kinases in herpes simplex virus replication and transcription. J. Virol. 72:1998;5626-5637.
29. Ye M., Duus K.M., Peng J., Price D.H., Grose C. Varicella-zoster virus Fc receptor component gI is phosphorylated on its endodomain by a cyclin-dependent kinase. J. Virol. 73:1999;1320-1330.
30. Imahori K., Uchida T. Physiology and pathology of tau protein kinases in relation to Alzheimer's disease. J. Biochem. 121:1997;179-188.
31. Mandelkow E.-M., Mandelkow E. Tau in Alzheimer's disease. Trends Cell Biol. 8:1998;425-427.
32. 1 kinase during the sea urchin egg mitotic divisions. Exp. Cell Res. 174:1988;116-129.
33. Néant I., Guerrier P. 6-Dimethylaminopurine blocks starfish oocyte maturation by inhibiting a relevant protein kinase activity. Exp. Cell Res. 176:1988;68-79.
34. Legraverend M., Ludwig O., Bisagni E., Leclerc S., Meijer L. Synthesis of C2 alkynylated purines, a new family of potent inhibitors of cyclin-dependent kinases. Bioorg. Med. Chem. Lett. 8:1998;793-798.
35. Norman T.C., Gray N.S., Koh J.T., Schultz P.G. A structure-based library approach to kinase inhibitors. J. Am. Chem. Soc. 118:1996;7430-7431.
36. Gray N.S., Schultz P.G. Combinatorial synthesis of 2,9-substituted purines. Tetrahedron Lett. 38:1997;1161-1164.
37. Nugiel D.A., Cornelius L.A.M., Corbett J.W. Facile preparation of 2,6-disubstituted purines using solid phase chemistry. J. Org. Chem. 62:1997;201-203.
38. Chang Y.T., Schultz P.G.et al. Synthesis and application of 2,6,9-trisubstituted purine library towards the development of functionally diverse CDK inhibitors. Chem. Biol. 6:1999;361-375.
39. Meijer L., Mordret G. Starfish oocyte maturation: from prophase to metaphase. Semin. Dev. Biol. 5:1994;165-171.
40. cdc2 on its Thr-14 and Tyr-15 residues at the prophase/metaphase transition. J. Biol. Chem. 271:1996;27847-27854.
41. Meijer L., Durchon M. Contrôle neurohormonal de la maturation des ovocytes chez Arenicola marina (Annélide Polychète). C.R. Acad. Sci. Paris. 285:1977;377-380. Etude in vitro [Neurohormonal control of oocyte maturation in Arericola marina: in vivo study].
42. cdc2 for tyrosine phosphorylation. EMBO J. 10:1991;1545-1554.
43. Rosania G.R., Merlie J., Gray N., Chang Y-T., Schultz P.G., Heald R. A cyclin-dependent kinase inhibitor inducing cancer cell differentiation: biochemical identification using Xenopus egg extracts. Proc. Natl. Acad. Sci. USA. 96:1999;4797-4802.
44. Barik S., Taylor R.E., Chakrabarti D. Identification, cloning, and mutational analysis of the casein kinase 1 cDNA of the malaria parasite, Plasmodium falciparum. J. Biol. Chem. 272:1997;26132-26138.
45. Hanks S.K., Hunter T. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification. FASEB J. 9:1995;576-596.
46. Schulze-Gahmen U., Kim S.-H.et al. Multiple modes of ligand recognition: crystal structures of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine. Proteins. 22:1995;378-391.
47. Schulze-Gahmen U., De Bondt H.L., Kim S.-H. High-resolution crystal structures of human cyclin-dependent kinase 2 with and without ATP: bound waters and natural ligand as guides for inhibitor design. J. Med. Chem. 39:1996;4540-4546.
48. Wang Z., Goldsmith E.J.et al. Structural basis of inhibitor selectivity in MAP kinases. Structure. 6:1998;1117-1128.
49. Doerig C., Chakrabarti D., Kappes B., Matthews K. The cell cycle in protozoan parasites. Meijer L., Jezequel A., Ducommun B. Progress in Cell Cycle Research, vol. 4. 2000;163-183 Plenum Press, New York.